Hydroponic Cultivation in Systemic Nickel Allergy Syndrome (DATTERINO)

April 2, 2022 updated by: Eleonora Nucera, Catholic University of the Sacred Heart

Hydroponic Cultivation: a New Dietary Frontier in Systemic Nickel Allergy Syndrome - a Double Blind, Randomized, Controlled, Cross-over, Clinical Trial on the Use of Hydroponic Cultivated Tomato Sauce

Oral intake of nickel (Ni) is capable of causing the onset of systemic disorders in patients with Systemic Allergy to Nickel Syndrome (SNAS), an emerging allergic condition. Given its ubiquitous age, it is not possible to completely eliminate Ni and, therefore, it is necessary to plan a low-content diet. However, due to various factors (such as variability of Ni concentration in the soil, individual foods, variability of dietary habits and daily menus, different intake of Ni contained in the water, different intake of kitchen utensils, simultaneous intake of other substances), a restrictive diet is difficult and socially discriminating with a strongly negative impact on the quality of life of these patients.

Hydroponic agriculture in a completely controlled, aseptic, artificial, soilless environment could be an alternative for patients suffering from SNAS with known and lower concentrations of metals than those deriving from conventional agricultural techniques, which are affected by the soil of origin and practices cultivation.

The primary outcome of the study is to evaluate the possible effects of taking tomato puree deriving from hydroponic agriculture compared to tomato puree from conventional cultivation in the subjective control of SNAS symptoms, in patients following a low-diet diet.

This is an interventional, randomized, double-blind, single-center crossover study involving a cohort of SNAS patients following a low-nickel diet for at least 4-6 weeks.

Study Overview

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Roma, Italy, 00168
        • UOSD Allergologia e Immunologia Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with documented diagnosis of SNAS: a) history of SNAS (coexistence of typical skin symptoms and gastrointestinal symptoms); b) positive nickel sulphate patch test; c) clinical improvement of at least 70% after 4-6 weeks of low-nickel diet; d) positivity of the oral challenge test with nickel sulphate.
  • Age between 18 and 65 years.
  • Written informed consent to participate in the study.
  • Patients who are able to participate in all study procedures and to accept and comply with all study needs throughout the study, including the availability of suitable transportation and the time required to undergo all procedures. planned visits.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Patients diagnosed with organic diseases capable of affecting gastrointestinal symptoms (eg celiac disease, poorly controlled diabetes, scleroderma, chronic inflammatory bowel diseases). Lactose intolerance is not an exclusion criterion if the diagnosis has been made for more than 6 months and if the patient does not report adequate symptom relief after at least 6 months of a lactose-free diet.
  • Patients who have been taking systemic probiotics, antibiotics or systemic corticosteroids within the past 30 days.
  • Patients who have been taking antidepressant or anxiolytic drugs for less than a month. On the other hand, patients can be enrolled who have been taking the aforementioned drugs at a stable dosage for at least one month.
  • Patients who abuse coffee, tea, coca cola and with a smoking habit.
  • Patients with pacemakers because they cannot be subjected to bioimpedance analysis for the assessment of body composition.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Datterino tomato purée from hydroponic technology
100% Italian datterino tomato purée deriving from hydroponic technology (soilless) with particular characteristics such as nickel free and zero residue.
Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
Active Comparator: Datterino tomato purée from conventional cultivation
100% Italian datterino tomato purée deriving from conventional cultivation.
Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of gastrointestinal symptoms control
Time Frame: Immediately after the intervention

Average values of the scores relating to the individual SNAS symptoms as reported in the visual analogue scale (VAS) - Systemic Nickel Allergy Syndrome (SNAS) scale before and after taking each type of tomato sauce (hydroponic vs conventional).

This scale includes values from a minimum of zero to a maximum of ten. Higher scores indicate a worse outcome.

Immediately after the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of impact on quality of life - SF-36
Time Frame: Change from baseline index at 12 and 26 weeks.

Difference in mean scores on quality of life questionnaire Short Form 36 Items Health Survey (SF-36) before and after each planned dietary treatment (hydroponic vs conventional tomato).

Each patient answers SF-36v2 (Italian version) questionnaire. It comprises 36-items measuring 8 dimensions of general QoL. Each question's score is coded, summed up, and transformed to a scale of 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).

Change from baseline index at 12 and 26 weeks.
Change of impact on quality of life - PGWBI
Time Frame: Change from baseline index at 12 and 26 weeks.

Difference in mean scores on quality of life questionnaire Psychological General Well Being Index (PGWBI) before and after each planned dietary treatment (hydroponic vs conventional tomato).

PGWBI consists of 22 questions, which deal with 6 factors (anxiety, depression, vitality, general health,self-control and well-being) constituting a global assessment. The response format is graded 1-6. This index includes values from a minimum of 0 to a maximum of 110. Higher scores indicate a better outcome.

Change from baseline index at 12 and 26 weeks.
Change of intestinal permeability
Time Frame: Change from baseline index at 12 and 26 weeks.
Difference in mean values of serum zonulin (a biomarker of intestinal permeability) before and after each planned dietary treatment (hydroponic vs conventional tomato puree).
Change from baseline index at 12 and 26 weeks.
Change of beta-carotene
Time Frame: Change from baseline index at 12 and 26 weeks.
Difference in the average values of beta-carotene [microg/dl] before and after each planned dietary treatment (hydroponic vs conventional tomato puree).
Change from baseline index at 12 and 26 weeks.
Change of Vitamin D
Time Frame: Change from baseline index at 12 and 26 weeks.
Difference in the average values of Vitamin D [ng/ml] before and after each planned dietary treatment (hydroponic vs conventional tomato puree).
Change from baseline index at 12 and 26 weeks.
Change of hemoglobin
Time Frame: Change from baseline index at 12 and 26 weeks.
Difference in the average values of hemoglobin [g/dl] before and after each planned dietary treatment (hydroponic vs conventional tomato puree).
Change from baseline index at 12 and 26 weeks.
Change of ferritin
Time Frame: Change from baseline index at 12 and 26 weeks.
Difference in the average values of ferritin [ng/ml] before and after each planned dietary treatment (hydroponic vs conventional tomato puree).
Change from baseline index at 12 and 26 weeks.
Change of adherence
Time Frame: After 12 weeks, after 26 weeks.
Cross-comparison between the percentages of weekly intake [average number of days per week] of tomato puree (hydroponic tomato puree before and conventional after versus conventional tomato puree before and hydroponic after).
After 12 weeks, after 26 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Eleonora Nucera, Prof., MD, Catholic University Of Sacred Heart
  • Principal Investigator: Angela Rizzi, MD, PhD, Catholic University Of Sacred Heart
  • Study Director: Antonio Gasbarrini, Prof., MD, Catholic University Of Sacred Heart

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 26, 2021

Primary Completion (Actual)

February 28, 2022

Study Completion (Actual)

March 31, 2022

Study Registration Dates

First Submitted

November 17, 2021

First Submitted That Met QC Criteria

January 31, 2022

First Posted (Actual)

February 10, 2022

Study Record Updates

Last Update Posted (Actual)

April 5, 2022

Last Update Submitted That Met QC Criteria

April 2, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Food Hypersensitivity

3
Subscribe